Heather McArthur

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. ncbi Adjuvant chemotherapy for early-stage breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 21:207-22. 2007
  2. ncbi Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 117:5461-8. 2011
  3. ncbi A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:3398-407. 2011
  4. ncbi Breast cancer chemotherapy
    Heather L McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer J 13:141-7. 2007
  5. ncbi Has first-line therapy had an impact on general outcome in metastatic breast cancer?
    Heather L McArthur
    Memorial Sloan Kettering Cancer Center, c o Sherdina Erwin, Breast Cancer Medicine Service, Department of Medicine, 1275 York Ave, New York, NY 10021, USA
    Future Oncol 3:411-8. 2007
  6. ncbi An overview of HER-targeted therapy with lapatinib in breast cancer
    Heather McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA
    Adv Ther 26:263-71. 2009
  7. ncbi Dose-dense therapy in the treatment of early-stage breast cancer: an overview of the data
    Heather L McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Clin Breast Cancer 8:S6-S10. 2007
  8. ncbi Biomarkers in breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer Biol Ther 7:21-2. 2008
  9. ncbi Current status of the taxanes as adjuvant therapy for breast cancer
    Clifford Hudis
    Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, MSKCC, 1275 York Avenue, New York, NY, USA
    Breast 16:S132-5. 2007
  10. ncbi Advances in adjuvant chemotherapy of early stage breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer Treat Res 141:37-53. 2008

Detail Information

Publications12

  1. ncbi Adjuvant chemotherapy for early-stage breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Hematol Oncol Clin North Am 21:207-22. 2007
    ....
  2. ncbi Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Cancer 117:5461-8. 2011
    ..Therefore, a retrospective, single-institution, sequential cohort study of women with small, node-negative, HER2+ breast cancer who did or did not receive adjuvant trastuzumab was conducted...
  3. ncbi A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
    Clin Cancer Res 17:3398-407. 2011
    ..We evaluated the cardiac safety of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (ddAC) → nanoparticle albumin-bound (nab)-paclitaxel in human epidermal growth factor receptor 2 normal early-stage breast cancer...
  4. ncbi Breast cancer chemotherapy
    Heather L McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Cancer J 13:141-7. 2007
    ..In this article we will review the role of important prognostic and predictive factors and the rationale for adjuvant systemic therapy and modern chemotherapy regimens in the management of women with early-stage breast cancer...
  5. ncbi Has first-line therapy had an impact on general outcome in metastatic breast cancer?
    Heather L McArthur
    Memorial Sloan Kettering Cancer Center, c o Sherdina Erwin, Breast Cancer Medicine Service, Department of Medicine, 1275 York Ave, New York, NY 10021, USA
    Future Oncol 3:411-8. 2007
    ..One hopes that ongoing innovations, particularly in targeted therapy, will continue to translate into further improvements in this population...
  6. ncbi An overview of HER-targeted therapy with lapatinib in breast cancer
    Heather McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY, 10065, USA
    Adv Ther 26:263-71. 2009
    ..However, the ideal strategy for incorporating novel HER2-targeted agents, including lapatinib, into existing management paradigms is uncertain...
  7. ncbi Dose-dense therapy in the treatment of early-stage breast cancer: an overview of the data
    Heather L McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Clin Breast Cancer 8:S6-S10. 2007
    ..Dose density has since been applied to a number of other chemotherapy regimens and evaluated in clinical trials. An overview of the pivotal dose-dense trials will be reviewed herein...
  8. ncbi Biomarkers in breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer Biol Ther 7:21-2. 2008
  9. ncbi Current status of the taxanes as adjuvant therapy for breast cancer
    Clifford Hudis
    Solid Tumor Division, Department of Medicine, Memorial Sloan Kettering Cancer Center, MSKCC, 1275 York Avenue, New York, NY, USA
    Breast 16:S132-5. 2007
    ..These trials are generally positive but do not clearly identify a single best or ideal regimen for all patients. This paper reviews the available data in this area of clinical research...
  10. ncbi Advances in adjuvant chemotherapy of early stage breast cancer
    Heather L McArthur
    Breast Cancer Medicine Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
    Cancer Treat Res 141:37-53. 2008
  11. ncbi Cardiotoxicity of trastuzumab in clinical practice
    Heather L McArthur
    N Engl J Med 357:94-5. 2007
  12. ncbi Intravascular hemolysis as a complication of clostridium perfringens sepsis
    Heather L McArthur
    Division of Medical Oncology, British Columbia Cancer Agency-Vancouver Cancer Centre, and Vancouver General Hospital, Vancouver, BC, Canada
    J Clin Oncol 24:2387-8. 2006